Fiscal year 2023 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses CMRX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CMRX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Mike Sherman | $514,695 | $0 | $183,112 | $778,511 | $0 | $0 | $41,536 | $1,517,854 |
| Former President and Chief Executive Officer | ||||||||
| Mike Andriole | 528,473 | 0 | 93,135 | 399,282 | 280,500 | 0 | 11,031 | 1,312,421 |
| President and Chief Executive Officer | ||||||||
| Allen Melemed | 488,408 | 0 | 50,708 | 215,588 | 166,059 | 0 | 11,031 | 931,794 |
| Chief Medical Officer | ||||||||
| Michael Alrutz | 432,180 | 0 | 42,257 | 179,656 | 128,574 | 0 | 11,187 | 793,854 |
| Senior Vice President, General Counsel and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Mike Sherman | $1,517,854 | $4,061,403 | — | −2,543,549 |
| Mike Andriole | 1,312,421 | 1,672,620 | — | −360,199 |
| Allen Melemed | 931,794 | 1,472,116 | — | −540,322 |
| Michael Alrutz | 793,854 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| On Aug | Options/SARs | — | — | — | 150,000 | — | $25,000 |
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Mike Sherman | Option | 13,179 | 2.08 | — |
| Allen Melemed | Option | 50,000 | 3.11 | — |
| Allen Melemed | Option | 118,909 | 1.97 | — |
| Michael Alrutz | Option | 99,091 | 1.97 | — |
| Allen Melemed | RSU | 25,740 | — | 24,775 |
| Michael Alrutz | RSU | 21,450 | — | 20,646 |
| Mike Andriole | Option | 67,708 | 9.28 | — |
| Mike Andriole | RSU | 32,175 | — | 30,968 |
| Mike Andriole | RSU | 25,000 | — | 24,063 |
| Mike Sherman | RSU | 92,950 | — | 89,464 |
| Allen Melemed | Option | 51,459 | 9.28 | — |
| Mike Andriole | Option | 156,250 | 5.62 | — |
| Mike Andriole | Option | 150,000 | 1.19 | — |
| Mike Sherman | Option | 455,730 | 5.62 | — |
| Michael Alrutz | Option | 46,042 | 9.28 | — |
| Mike Sherman | Option | 189,584 | 9.28 | — |
| Mike Andriole | Option | 4,011 | 2.08 | — |
| Mike Andriole | Option | 148,636 | 1.97 | — |
| Allen Melemed | Option | 125,000 | 5.62 | — |
| Michael Alrutz | Option | 3,438 | 2.08 | — |
| Michael Alrutz | Option | 104,167 | 5.62 | — |
| Mike Sherman | Option | 429,393 | 1.97 | — |
our executive compensation program embodies a pay-for-performance philosophy that supports our business strategy and aligns the interests of our executives with our stockholders. In particular, our compensation program rewards financial, strategic and operational performance and the goals set for each performance category are intended to support our long-range plans.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon plc (Human Capital Solutions practice) |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Mike ShermanIndependent · Board Chair | $31,182 | $183,112 | $778,511 | — | $0 | $992,805 |
| Martha J. DemskiIndependent · Lead Independent Director · Audit (Chair) | 85,000 | 0 | 59,522 | — | 0 | 144,522 |
| Patrick MachadoIndependent · Audit · Not standing for re-election | 65,000 | 0 | 59,522 | — | 0 | 124,522 |
| Fred A. MiddletonIndependent · Compensation (Chair) | 60,000 | 0 | 59,522 | — | 0 | 119,522 |
| Robert J. MeyerIndependent · Nominating/Governance (Chair) | 57,500 | 0 | 59,522 | — | 0 | 117,022 |
| Vicki VakienerIndependent · Compensation · Audit | 47,500 | 0 | 59,522 | — | 0 | 107,022 |
| Pratik S. MultaniIndependent · Nominating/Governance | 45,000 | 0 | 59,522 | — | 0 | 104,522 |
| Catherine L. GillissIndependent · Nominating/Governance · Departed during FY | 45,000 | 0 | 59,522 | — | 0 | 104,522 |
| Lisa L. DeckerIndependent · Nominating/Governance · Newly elected | 0 | 0 | 67,778 | — | 0 | 67,778 |
| Marc D. KozinIndependent · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
| Mike AndrioleEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $436,182 |
| Equity awards (grant-date value) | $183,112 |
| All other compensation | $0 |
| Total cost of the board | $619,294 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Chimerix names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Chimerix.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Ardelyx | 2025 | Michael Raab | $797,000 | $2,953,724 | $3,413,948 | $627,638 | $7,796,171 |
| 2 | Y-mAbs Therapeutics | 2024 | Michael Rossi | 705,600 | 1,170,732 | 2,288,662 | 392,596 | 4,557,590 |
| 3 | Precision BioSciences | 2025 | Michael Amoroso | 650,875 | 1,025,086 | 0 | 0 | 2,189,467 |
| 4 | Seres Therapeutics | 2025 | Eric Shaff | 408,333 | 0 | 1,338,870 | 0 | 1,775,549 |
| 5 | Arcturus Therapeutics | 2025 | Joseph Payne | 750,000 | 0 | 941,000 | 0 | 1,691,000 |
| 6 | Chimerix | 2023 | Mike Andriole | 528,473 | 93,135 | 399,282 | 280,500 | 1,312,421 |
| — | G1 Therapeutics | — | — | — | — | — | — | not in coverage universe |
| — | BioXcel Therapeutics | — | — | — | — | — | — | not in coverage universe |
| — | ALX Oncology | — | — | — | — | — | — | not in coverage universe |
| — | Curis | — | — | — | — | — | — | not in coverage universe |
| — | VBI Vaccines | — | — | — | — | — | — | not in coverage universe |
| — | CymaBay Therapeutics | — | — | — | — | — | — | not in coverage universe |
| — | Gritstone bio | — | — | — | — | — | — | not in coverage universe |
| — | CytomX Therapeutics | — | — | — | — | — | — | not in coverage universe |
| — | Trevena | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Chimerix | not disclosed | Options 86 · RSU 14 | not disclosed | Aon plc (Human Capital Solutions practice) |
| ALX Oncology | not disclosed | not disclosed | not disclosed | not disclosed |
| Arcturus Therapeutics | not disclosed | Options 100 | not disclosed | not disclosed |
| Ardelyx | 105% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| BioXcel Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Curis | not disclosed | not disclosed | not disclosed | not disclosed |
| CymaBay Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| CytomX Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| G1 Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Gritstone bio | not disclosed | not disclosed | not disclosed | not disclosed |
| Precision BioSciences | 115% | RSU 100 | not disclosed | Aon |
| Seres Therapeutics | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| Trevena | not disclosed | not disclosed | not disclosed | not disclosed |
| VBI Vaccines | not disclosed | not disclosed | not disclosed | not disclosed |
| Y-mAbs Therapeutics | 85.6% | PSU 34 · Options 33 · RSU 33 | No | Aon's Human Capital Solutions practice (division of Aon plc) |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Mike Sherman | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Summary Compensation Table”. As printed: 1,517,854. Filing ↗machine: t16 · r5 · c8 · span 480989–480998 |
| 2 | Section 01, Mike Andriole | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Summary Compensation Table”. As printed: 1,312,421. Filing ↗machine: t16 · r2 · c8 · span 463873–463882 |
| 3 | Section 01, Allen Melemed | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Summary Compensation Table”. As printed: 931,794. Filing ↗machine: t16 · r3 · c8 · span 470620–470627 |
| 4 | Section 01, Michael Alrutz | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Summary Compensation Table”. As printed: 793,854. Filing ↗machine: r4 · c24 · span 474795–474802 |
| 5 | Section 03, On Aug Options/SARs | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “EXECUTIVE AND DIRECTOR COMPENSATION EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t18 · r6 · c0 · span 511586–511592 |
| 6 | Section 08, Mike Sherman | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 992,805. Filing ↗ |
| 7 | Section 08, Martha J. Demski | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 144,522. Filing ↗machine: t23 · r3 · c8 · span 677379–677386 |
| 8 | Section 08, Patrick Machado | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 124,522. Filing ↗machine: t23 · r5 · c8 · span 679967–679974 |
| 9 | Section 08, Fred A. Middleton | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 119,522. Filing ↗machine: t23 · r7 · c8 · span 682353–682360 |
| 10 | Section 08, Robert J. Meyer | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 117,022. Filing ↗machine: t23 · r6 · c8 · span 681162–681169 |
| 11 | Section 08, Vicki Vakiener | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 107,022. Filing ↗machine: t23 · r9 · c8 · span 684878–684885 |
| 12 | Section 08, Pratik S. Multani | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 104,522. Filing ↗machine: t23 · r8 · c8 · span 683550–683557 |
| 13 | Section 08, Catherine L. Gilliss | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 104,522. Filing ↗machine: t23 · r4 · c8 · span 678778–678785 |
| 14 | Section 08, Lisa L. Decker | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 67,778. Filing ↗machine: t23 · r2 · c5 · span 675868–675874 |
| 15 | Section 08, Marc D. Kozin | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 16 | Section 08, Mike Andriole | DEF 14A | 2024-04-26 | 0001117480-24-000010 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 17 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 18 | Section 09b board cost (computed) | Computed | — | computed | Cash 436,182 + equity 183,112 + all other 0 = 619,294, summed across the director compensation table rows.machine: formula: Σ = 619,294 |
| 19 | Ardelyx, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001140361-26-017800 | CEO total compensation as printed in Ardelyx's own proxy. As printed: 7,796,171. Filing ↗machine: r2 · c25 · span 677112–677121 |
| 20 | Y-mAbs Therapeutics, Section 10b CEO total | DEF 14A | 2025-05-30 | 0001558370-25-008299 | CEO total compensation as printed in Y-mAbs Therapeutics's own proxy. As printed: 4,557,590. Filing ↗machine: t100 · r5 · c23 · span 597595–597604 |
| 21 | Precision BioSciences, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001140361-26-013757 | CEO total compensation as printed in Precision BioSciences's own proxy. As printed: 2,189,467. Filing ↗machine: r2 · c19 · span 829996–830005 |
| 22 | Seres Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-182036 | CEO total compensation as printed in Seres Therapeutics's own proxy. As printed: 1,775,549. Filing ↗machine: r2 · c29 · span 928055–928064 |
| 23 | Arcturus Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193805-26-000507 | CEO total compensation as printed in Arcturus Therapeutics's own proxy. As printed: 1,691,000. Filing ↗machine: t116 · r1 · c27 · span 296910–296919 |
| 24 | Chimerix (subject), Section 10b CEO total | DEF 14A | 2024-04-26 | 0001117480-24-000010 | CEO total compensation as printed in Chimerix's own proxy. As printed: 1,312,421. Filing ↗machine: t16 · r2 · c8 · span 463873–463882 |
| 25 | Section 10a, Ardelyx reciprocity | DEF 14A | — | 0001140361-26-017800 | Ardelyx's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗ |
| 26 | Section 10a, Arcturus Therapeutics reciprocity | DEF 14A | — | 0001193805-26-000507 | Arcturus Therapeutics's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗ |
| 27 | Section 10a, Seres Therapeutics reciprocity | DEF 14A | — | 0001193125-26-182036 | Seres Therapeutics's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗ |
| 28 | Section 10a, Precision BioSciences reciprocity | DEF 14A | — | 0001140361-26-013757 | Precision BioSciences's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗ |
| 29 | Section 10a, Y-mAbs Therapeutics reciprocity | DEF 14A | — | 0001558370-25-008299 | Y-mAbs Therapeutics's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗ |